Therapeutic Anticoagulation in Non-Critically Ill Patients with Covid-19
Authors:
Preprint
Abstract
Background Thrombo-inflammation may contribute to morbidity and mortality in Covid-19. We hypothesized that therapeutic-dose anticoagulation may improve outcomes in non-critically ill patients hospitalized for Covid-19. Methods In an open-label adaptive multiplatform randomized controlled trial, non-critically ill patients hospitalized for Covid-19, defined by the absence of critical care-level organ support at enrollment, were randomized to a pragmatic strategy of therapeutic-dose anticoagulation with heparin or usual care pharmacological thromboprophylaxis. The primary outcome combined survival to hospital discharge and days free of organ support through 21 days, which was evaluated with Bayesian statistical models according to baseline D-dimer. Results The trial was stopped when prespecified criteria for superiority were met for therapeutic-dose anticoagulation in groups defined by high (≥2-fold elevated) and low (Conclusions In non-critically ill patients with Covid-19, an initial strategy of therapeutic-dose anticoagulation with heparin increases the probability of survival to hospital discharge with reduced use of organ support. Trial registration numbers: NCT02735707, NCT04505774, NCT04359277, NCT04372589Keywords
This publication has 32 references indexed in Scilit:
- Patient Trajectories Among Persons Hospitalized for COVID-19Annals of Internal Medicine, 2021
- Heparin Inhibits Cellular Invasion by SARS-CoV-2: Structural Dependence of the Interaction of the Spike S1 Receptor-Binding Domain with HeparinThrombosis and Haemostasis, 2020
- SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2Cell, 2020
- Anticoagulation in Hospitalized Patients with Covid-19New England Journal of Medicine, 2020
- Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patientsEBioMedicine, 2020
- Anticipating and managing coagulopathy and thrombotic manifestations of severe COVID-19Canadian Medical Association Journal, 2020
- Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health SystemJAMA, 2020
- Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City AreaJAMA, 2020
- Incidence, clinical outcomes, and transmission dynamics of severe coronavirus disease 2019 in California and Washington: prospective cohort studyBMJ, 2020
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort studyThe Lancet, 2020